Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62

NCT00216112 is registered in ClinicalTrials.gov with Daniela Matei, MD as lead sponsor.

NCT NCT00216112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62
Lead sponsor
Daniela Matei, MD
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
July 31, 2007
Enrollment
23 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer